BirchBioMed

Develop life-changing treatments to solve unmet medical needs

BirchBioMed is a clinical-stage biopharmaceutical company, founded in 2015 as a spin-off from the University of British Columbia (UBC), focused on developing novel therapies for diseases with significant unmet medical need. The company specializes in anti-fibrotic and immune-modulating treatments, targeting conditions such as organ fibrosis, scarring, inflammatory skin diseases, and select autoimmune disorders. BirchBioMed holds exclusive worldwide licenses to proprietary technologies developed at UBC and is advancing both topical and systemic drug candidates through clinical development, with the aim of delivering transformative, potentially disease-modifying therapies.